Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1951 2
1952 1
1960 1
1975 1
1979 2
1981 1
1983 1
1984 1
1985 7
1986 8
1987 4
1988 19
1989 15
1990 42
1991 38
1992 62
1993 66
1994 74
1995 77
1996 62
1997 48
1998 42
1999 39
2000 23
2001 37
2002 19
2003 22
2004 23
2005 26
2006 19
2007 19
2008 19
2009 12
2010 15
2011 11
2012 17
2013 13
2014 16
2015 18
2016 11
2017 7
2018 10
2019 7
2020 17
2021 12
2022 8
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

961 results

Results by year

Filters applied: . Clear all
Page 1
100 Years of Suramin.
Wiedemar N, Hauser DA, Mäser P. Wiedemar N, et al. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e01168-19. doi: 10.1128/AAC.01168-19. Print 2020 Feb 21. Antimicrob Agents Chemother. 2020. PMID: 31844000 Free PMC article. Review.
Suramin is 100 years old and is still being used to treat the first stage of acute human sleeping sickness, caused by Trypanosoma bruceirhodesiense Suramin is a multifunctional molecule with a wide array of potential applications, from parasitic and viral diseases t
Suramin is 100 years old and is still being used to treat the first stage of acute human sleeping sickness, caused by Trypanosoma bru
Suramin.
Eisenberger MA, Reyno LM. Eisenberger MA, et al. Cancer Treat Rev. 1994 Jul;20(3):259-73. doi: 10.1016/0305-7372(94)90003-5. Cancer Treat Rev. 1994. PMID: 8020006 Review. No abstract available.
Suramin's development: what did we learn?
Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Kaur M, et al. Invest New Drugs. 2002 May;20(2):209-19. doi: 10.1023/a:1015666024386. Invest New Drugs. 2002. PMID: 12099581 Review.
Suramin, a polysulphonated napthylurea, has been extensively evaluated over the past 10 years as an anticancer agent, with the most interest in the treatment of prostate cancer. ...These lessons can be applied to all clinical trials in hormone refractory prostate
Suramin, a polysulphonated napthylurea, has been extensively evaluated over the past 10 years as an anticancer agent, with the most i
Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.
Cheng B, Gao F, Maissy E, Xu P. Cheng B, et al. Acta Biomater. 2019 Jan 15;84:378-390. doi: 10.1016/j.actbio.2018.12.010. Epub 2018 Dec 5. Acta Biomater. 2019. PMID: 30528604 Free PMC article.
Suramin (SM), a drug for African sleeping sickness and river blindness therapy, has been investigated in various clinical trials for cancer therapy. ...As all the components used in this system are biocompatible and easy for large-scale fabrication, the GCS-SM/DOX s
Suramin (SM), a drug for African sleeping sickness and river blindness therapy, has been investigated in various clinical trials for
Suramin awakes?
Pinedo HM, van Rijswijk RE. Pinedo HM, et al. J Clin Oncol. 1992 Jun;10(6):875-7. doi: 10.1200/JCO.1992.10.6.875. J Clin Oncol. 1992. PMID: 1588368 No abstract available.
Suramin-induced polyneuropathy.
La Rocca RV, Meer J, Gilliatt RW, Stein CA, Cassidy J, Myers CE, Dalakas MC. La Rocca RV, et al. Neurology. 1990 Jun;40(6):954-60. doi: 10.1212/wnl.40.6.954. Neurology. 1990. PMID: 2161094
No correlation could be made with the total dose of suramin administered or with the duration of therapy. Two of these 4 patients manifested tumor shrinkage while receiving suramin therapy. We conclude that suramin, a promising antineoplastic agent, is capabl …
No correlation could be made with the total dose of suramin administered or with the duration of therapy. Two of these 4 patients man …
Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin.
Zaragoza-Huesca D, Rodenas MC, Peñas-Martínez J, Pardo-Sánchez I, Peña-García J, Espín S, Ricote G, Nieto A, García-Molina F, Vicente V, Lozano ML, Carmona-Bayonas A, Mulero V, Pérez-Sánchez H, Martínez-Martínez I. Zaragoza-Huesca D, et al. Biomed Pharmacother. 2023 Dec;168:115814. doi: 10.1016/j.biopha.2023.115814. Epub 2023 Oct 31. Biomed Pharmacother. 2023. PMID: 37918256 Free article.
Suramin did not reduce the thrombotic phenotype in the hepsin-negative colorectal cancer cells HCT-116 and DLD-1. ...CONCLUSION: Suramin is a novel hepsin inhibitor that reduces its protumorigenic and prothrombotic effects in colorectal cancer cells. .
Suramin did not reduce the thrombotic phenotype in the hepsin-negative colorectal cancer cells HCT-116 and DLD-1. ...CONCLUSIO
Suramin.
Eisenberger MA, Sinibaldi V, Reyno L. Eisenberger MA, et al. Cancer Pract. 1995 May-Jun;3(3):187-9. Cancer Pract. 1995. PMID: 7599677 Review. No abstract available.
Spatial modeling of prostate cancer metabolic gene expression reveals extensive heterogeneity and selective vulnerabilities.
Wang Y, Ma S, Ruzzo WL. Wang Y, et al. Sci Rep. 2020 Feb 26;10(1):3490. doi: 10.1038/s41598-020-60384-w. Sci Rep. 2020. PMID: 32103057 Free PMC article.
Therefore, we predicted that inhibiting the prostaglandin transporter SLCO2A1 may selectively kill cancer cells. Importantly, SCD1 and SLCO2A1 have been previously shown to be potently and selectively inhibited by compounds such as CAY10566 and suramin, respectively …
Therefore, we predicted that inhibiting the prostaglandin transporter SLCO2A1 may selectively kill cancer cells. Importantly, SCD1 an …
961 results